Biogen Idec, Inc. (Massachusetts), Elan Corporation PLC Shares Fall on FDA Concerns

July 31, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NEW YORK - Shares of biotechnology companies Biogen Idec Inc. and Elan Corp. fell Monday on concerns a Food and Drug Administration panel may recommend against approving Tysabri as a Crohn's disease treatment.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Postmarket research

Food and Drug Administration (FDA) Biogen